MedTrace Logo

Safety and Efficacy of Edoxaban and Rivaroxaban to Cerebral Venous Thrombosis in Chinese Patients

NCT06947707 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1486

Last updated 2025-04-27

No results posted yet for this study

Summary

The goal of this observational study is to learn the safety and efficacy of edoxaban and rivaroxaban in Chinese population with the age range from 18 to 80 years who take edoxaban or rivaroxaban to treat their cerebral venous thrombosis (CVT). The main question it aims to answer are:

* Do cerebral veins or venous sinuses recanalize during the treatment period of edoxaban and rivaroxaban?
* Do the bleeding events occur during the treatment period of edoxaban and rivaroxaban?

The main tasks participants will be asked to do:

* Participants will comply fully with the prescribed regimen and take the edoxaban or rivaroxaban as directed at the specified dosage.
* Participants will return to hospital for scheduled follow-up assessments at months 3, 6, 9, and 12 post-enrollment to undergo face-to-face visits with investigators.

Conditions

  • Cerebral Venous Thrombosis
  • Anticoagulants and Thrombotic Disorders
  • Anticoagulation Treatment
  • Anticoagulant Therapy
  • Anticoagulant Drugs
  • NOACs
  • Anticoagulant Prophylaxis/Therapy
  • Anticoagulation With NOAC
  • Anticoagulation With Direct Oral Anticoagulants

Sponsors & Collaborators

  • Xuanwu Hospital, Beijing

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-04-10
Primary Completion
2027-12-31
Completion
2027-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06947707 on ClinicalTrials.gov